Tuesday, November 24, 2009, 3:09pm SGT - The Singapore stock market closes in 1 hour and 51 minutes.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Neurogen Corp. (NRGN)

At 5:00AM SGT: 0.18 USD  Up 0.01 (5.88%)  
 MORE ON NRGN 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 Neurogen Corporation (NGM:NRGN) Delayed quote dataEdit
Last Trade:0.18 USD
Trade Time:5:00AM SGT
Change:Up 0.01 (5.88%)
Prev Close:0.17
Open:0.17
Bid:0.05 x 1000
Ask:0.38 x 400
1y Target Est:3.00
Day's Range:0.17 - 0.18
52wk Range:0.06 - 2.07
Volume:61,221
Avg Vol (3m):552,435
Market Cap:12.43M
P/E (ttm):N/A
EPS (ttm):-0.37
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add NRGN to Portfolio   Download Data

 HEADLINES 
•NEUROGEN CORP Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Thu, Nov 19)
•NEUROGEN CORP Financials
EDGAR Online Financials (Fri, Nov 13)
•New Star Analyst Rankings for Neurogen Corporation
StarMine (Tue, Nov 10)
•NEUROGEN CORP Files SEC form 10-Q/A, Quarterly Report
EDGAR Online (Tue, Nov 10)
•Neurogen Corporation Earnings Call scheduled for 8:30 am ET today
CCBN (Fri, Nov 6)
•NEUROGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and Financial Con
EDGAR Online (Fri, Nov 6)
•Neurogen Corporation Announces Third Quarter 2009 Financial Results and Updates Operations
Business Wire (Fri, Nov 6)
•Neurogen Corporation Announces Webcast of Third Quarter 2009 Financial Results on November 6
Business Wire (Thu, Nov 5)
•NEUROGEN CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Sta
EDGAR Online (Tue, Aug 25)
•Neurogen Corporation Earnings Call scheduled for 5:00 pm ET today
CCBN (Sat, Aug 15)
More Headlines for NRGN...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.38
EPS Est (in 2 years) (Dec-10) :-0.27
Avg Rec (current)*:5.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Neurogen Corporation engages in the development of new small molecule drugs for psychiatric and neurological disorders. The company’s clinical development programs include aplindore, which is in Phase II clinical trials for the treatment of P...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices